Royalty Rate Set In Boston, Cordis Stent Spat

Law360, New York (April 13, 2009, 12:00 AM EDT) -- Resolving all remaining issues in a seven-year dispute over stent patents, a federal judge has ruled that Boston Scientific Corp. must pay a 5.1 percent royalty rate on its sales of products infringing on Cordis Corp.'s patents.

The rate applies to catheters sold alone or as part of a stent delivery system, according to the order entered Thursday by U.S. District Judge Susan Illston in the U.S. District Court for the Northern District of California.

Boston Scientific and Johnson & Johnson's Cordis unit were unable to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.